Skip to main content
OpenTrials

Clinical trial condition

Myelodysplastic Syndromes

Explore clinical trials studying Myelodysplastic Syndromes. Study availability and eligibility vary by location and protocol.

279 public trials 59 recruiting studies
Refine in advanced search Browse all conditions

Myelodysplastic Syndromes trial results

Completed

Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy

NCT04820530

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Novartis Investigative Site Beijing, China
  • Novartis Investigative Site Tianjin, China
  • Novartis Investigative Site Tianjin, China
  • Novartis Investigative Site Paris, France
View Trial Details
Completed

Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

NCT04558918

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • City Of Hope National Med Center City of Hope Medical Center Duarte, California, United States
  • Univ Cali Irvine ALS Neuromuscular Orange, California, United States
  • Augusta University Georgia Patient Treatment Augusta, Georgia, United States
  • Levine Cancer Insitute Carolinas Healthcare System Charlotte, North Carolina, United States
View all 39 locations
View Trial Details
Completed

Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

NCT03748823

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Research Site Los Angeles, California, United States
  • Research Site Liverpool, Australia
  • Research Site Parkville, Australia
  • Research Site Vienna, Austria
View all 51 locations
View Trial Details
Completed

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT03896152

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +8 more
Locations
  • Novartis Investigative Site Kota Kinabalu, Sabah, Malaysia
  • Novartis Investigative Site Singapore
  • Novartis Investigative Site Seoul, South Korea
  • Novartis Investigative Site Seoul, South Korea
View Trial Details
Completed

ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT02946463

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Research Site Los Angeles, California, United States
  • Research Site Whittier, California, United States
  • Research Site Fort Worth, Texas, United States
  • Research Site Buenos Aires, Argentina
View all 120 locations
View Trial Details
Completed

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

NCT03959241

Conditions
Acute Leukemia, Anemia, Anemia, Refractory, +22 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • City of Hope National Medical Center Duarte, California, United States
  • University of California, San Francisco San Francisco, California, United States
  • Stanford Hospital and Clinics Stanford, California, United States
View all 39 locations
View Trial Details
Completed

A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria

NCT04058158

Conditions
Anemia, Anemia, Hemolytic, Bone Marrow Diseases, +5 more
Locations
  • Fortis Memorial Research Institute Gurgaon, Haryana, India
  • Post Graduate Institute of Medical Education and Research (PGIMER) Chandigarh, India
  • Apollo Hospitals International Limited Chennai, India
  • Amrita Institute of Medical Sciences and Research Centre Kochi, India
View all 27 locations
View Trial Details

Related conditions